ReachRxResearch
Home
Research
Sign Up
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy
Back to Research Hub
  1. Home
  2. Research Hub
  3. Complete Regression of Hepatoblastoma af…

Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy

New England Journal of Medicine·September 9
Medicine, General & InternalPractice changingHepatoblastomaCase ReportCAR T-Cell TherapyCytokine Gene-Modified Cell TherapyPediatricIL-15 And IL-21 Coexpressing CAR T-Cells

Summary

View source

What was studied

Evaluated the use of CAR T-cells co-expressing interleukin-15 (IL-15) and interleukin-21 (IL-21) in a patient with hepatoblastoma, assessing tumor response to this novel cellular therapy.

Key findings

Complete regression of hepatoblastoma was achieved following treatment with IL-15– and IL-21–coexpressing CAR T-cells.

Study limitations

Published as a case communication (letter), limiting generalizability; single patient report with no control comparator; long-term durability of response and safety profile not yet established.

Clinical implications

IL-15 and IL-21 co-expression in CAR T-cells may meaningfully enhance antitumor activity in pediatric hepatoblastoma. This early signal warrants follow-up in prospective trials before broader clinical adoption.

Caveats

  • Full safety profile, dosing details, and long-term follow-up data are not available from the provided source text alone.
  • Patient age and sex are not explicitly stated in the provided abstract; pediatric age group inferred from the condition (hepatoblastoma is predominantly a pediatric tumor).
  • This is a single case report (n=1) published as a letter in NEJM; the 'practice_changing' flag reflects novelty and potential signal strength, but clinical adoption should await larger prospective studies.

Related Questions

Explore related topics

What are the latest CAR T-cell therapies being studied for pediatric liver tumors?How do IL-15 and IL-21 cytokines improve CAR T-cell persistence and antitumor activity?What salvage options exist for refractory or relapsed hepatoblastoma in children?

Publication Details

Year
2026
Journal
New England Journal of Medicine
Sample Size
n=1
Source
View article
Keep scrolling
More content below.
Up Next